Novo Nordisk keeps growing, fuelling hopes of a stock rebound
The results were broadly in line with expectations. In the first six months of 2025, Novo Nordisk's sales increased by 16% in Danish kroner and by 18% at constant exchange rates (CER) to DKK 154.9bn (€20.77bn).
US sales climbed 16% in kroner (17% at CER), boosted by accounting changes. This included a DKK 3bn (€402 million) provision in the second quarter linked to the US' 340B drug discount scheme. International sales also rose 16% (19% at CER).
Sales in Diabetes and Obesity care, meanwhile, grew 16% to DKK 145.4bn (€19.49bn), driven by a 56% surge in obesity treatments to DKK 38.8 billion (€5.2bn). GLP-1 diabetes drugs rose 8%, and rare disease sales increased 14%.
Valuation slump
In July 2024, Danish pharmaceutical giant Novo Nordisk briefly touched a €600bn valuation, becoming Europe's most valuable company and even surpassing its country's gross domestic product.
Just over a year later, its market capitalisation has collapsed to around €180bn, as cracks begin to emerge in the blockbuster narrative surrounding its weight-loss drugs.
Yet some Wall Street analysts argue the sell-off may have gone too far. At current levels, they suggest the company could be entering value territory, potentially offering a compelling buying opportunity.
Forecasts for the year ahead
Looking ahead, Novo Nordisk's 2025 sales are expected to grow 8–14% at CER, with operating profit up 10–16%. Currency effects are seen trimming those gains by 3 and 5 percentage points respectively.
The lowered forecast reflects reduced demand for GLP-1 diabetes and weight-loss therapies due to alternative products from competitors — especially affecting Wegovy and Ozempic in the US and selected global markets.
Meanwhile, leadership changes at Novo Nordisk will take effect this Thursday. After Lars Fruergaard Jørgensen was ousted in May linked to the firm's falling share price, Maziar Mike Doustdar will take over as CEO this week.
Analysts eye buying opportunity after historic sell-off
Goldman Sachs analyst James Quigley noted that the results were largely in line with the pre-release and exchange-rate pressures on operating profit were slightly less severe than initially feared.
However, the firm flagged the discontinuation of several pipeline assets. These are individually minor, but collectively raising some concern about long-term research and development momentum.
Quigley remained broadly optimistic on Novo Nordisk's long-term potential growth: "At the current level, we believe the sell-off is disconnected from the long-term opportunity in the obesity market, particularly given the significant manufacturing infrastructure and investments Novo is making or has already made.'
Goldman Sachs acknowledged that uncertainties remain around the GLP-1 and obesity market, as well as Novo Nordisk's pipeline strength, particularly in light of the eventual semaglutide patent expiry.
The firm said it would continue tracking key data points and developments closely.
Still, Quigley added that, following the sharp share price drop, the risk-reward balance had shifted favourably.
"On balance, we see more upside than downside risk and remain Buy-rated," the note read, with a DKK 400 (€53.62) target price implying about 29% upside from current levels.
Market reaction
Novo Nordisk shares were trading 2% lower during European morning trading on Wednesday, eyeing their seventh negative day out of the last eight.
Shares are now down over 65% compared with a year ago.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Euronews
2 days ago
- Euronews
Portugal limits weight loss drug prescriptions to prevent misuse
Portugal is restricting doctors' ability to prescribe blockbuster weight loss drugs and monitors that track blood sugar levels, over concerns that they are being misused. As of Friday, only doctors from four medical specialties will be able to prescribe glucose sensors and drugs like Ozempic, Wegovy, and Mounjaro, which are known as glucagon-like peptide-1 (GLP-1) receptor agonists. Used to treat type 2 diabetes and obesity, the medicines help people lose weight by mimicking a hormone that makes them feel full for longer. The injectable drugs are in high demand, though, which has led to availability problems on the market. This is the case with Ozempic from the Danish laboratory Novo Nordisk. Ozempic is only approved in Portugal to treat type 2 diabetes, but it is highly sought after for weight loss. Mounjaro (Eli Lilly) and Wegovy (Novo Nordisk) are approved for both diabetes and obesity. In the first four months of 2025, Portuguese consumers spent around €21 million on these medicines. Now, only doctors from the approved specialties – endocrinology and nutrition, internal medicine, paediatrics, and general and family medicine – will be able to prescribe them. Glucose sensors have also been in high demand by non-diabetics, causing a shortage of these monitors in pharmacies. According to the Público newspaper, they are prescribed by doctors who do not work with diabetes patients, and are highly sought after by dieters, athletes, influencers, and even for use on animals. Portugal's Ministry of Health posted the regulation in April, warning of "recent reports of improper access to and use of these same technologies, which have jeopardised their availability to those who actually need them". "This decree aims to regulate and correct these distortions, promoting effective and adequate access to these essential health tools," the ministry said. The president of the Portuguese Society of Diabetology (SPD) praised the measure, but says it is late and may not solve the problem of difficult access to these medicines. "We're waiting to see if [the measure] will simplify or facilitate access," said João Raposo, speaking to the Lusa news agency. "I personally have some doubts, because I have the idea that the number of prescriptions outside of these specialties is not significant," Raposo added. He said that diabetics and doctors are not opposed to these drugs being used to treat obesity. But there are "anomalous prescriptions and a lack of monitoring of these people," he said. "Health cannot be subject to the laws of the market, because we know that it is very tempting for this population, which is desperately looking for solutions. The market has worked and we shouldn't have let it happen," he added. GLP-1 agonist medicines are reimbursed by the Portuguese state at 90 per cent. Sensor reimbursement can be as high as 85 per cent. In addition to prescriptions, there is also a high demand for these medicines on the black market, which can lead to problems with counterfeiting.
Sustainability Times
3 days ago
- Sustainability Times
'Donate Your Pets To Lions': Zoo's Shocking Plea Sparks Outrage And Heartbreak Across The Nation
IN A NUTSHELL 🦁 A Danish zoo has requested the public to donate unwanted small pets, such as rabbits, for its predators. 💬 The zoo defends the practice, citing the need to provide a more natural diet for their carnivores. for their carnivores. 🤔 Public reactions are mixed, with some questioning the ethical implications of using domestic pets as food. of using domestic pets as food. 🌍 This initiative may influence zoo feeding practices and policies worldwide. The recent initiative by a Danish zoo to invite pet owners to donate small, unwanted pets for predator consumption has sparked a global conversation. While many animal lovers express disdain at the idea of their cherished companions becoming part of the food chain, the zoo defends its policy as a commitment to animal welfare. This controversial practice raises questions about ethical zoo practices and the responsibility institutions have to mimic natural ecosystems. The Zoo's Controversial Request A Danish zoo has drawn international attention with its request for pet owners to donate unwanted small pets, such as hens, rabbits, and guinea pigs, for consumption by its predators. This initiative is not just about feeding the animals; it's an effort to replicate the natural diet of these carnivorous creatures. The zoo argues that offering prey animals with fur or feathers aligns with their mission to uphold animal welfare standards by simulating a more authentic food chain. The zoo's call to the public was made via a Facebook post, stating, 'In zoos, we have a responsibility to imitate the animals' natural food chain — for reasons of both animal welfare and professional integrity.' While this statement outlines their rationale, it has not shielded the institution from criticism. The ethical implications of using domestic pets as food, even if they are unwanted, remain a contentious topic. 'This Cat Saved My Life': Black Feline Leads Scientists to Hidden Human Virus That Could Rewrite Modern Medical Science Public Reaction and Ethical Concerns The public response has been mixed, with some expressing outright horror at the idea. A comedic yet telling comment from a woman questioned if children could be donated when they become troublesome, to which the zoo humorously replied that only animals with feathers or fur are accepted. This exchange highlights the unease and moral questions surrounding the practice. On the other hand, Pia Nielsen, the deputy director of the Aalborg Zoo, provided reassurance by explaining the commonality of this practice in Denmark. She emphasized the zoo's intention to give predators as natural a diet as possible, suggesting that many guests appreciate the opportunity to contribute. This stance, however, does not dispel the underlying ethical concerns about the treatment and use of domesticated animals. Scientists Stunned as Peacocks Found to Shoot 'Deadly Lasers' From Tails in Shocking Discovery That Could Change Everything About Nature Understanding the Zoo's Perspective From the zoo's viewpoint, providing a naturalistic diet to their predators is crucial. Nielsen reiterated that allowing animals that need to be euthanized to serve a purpose aligns with the zoo's mission. This not only reduces waste but also enhances the well-being of the zoo's carnivorous residents by providing them with food similar to what they would encounter in the wild. Despite this rationale, the practice challenges traditional views on pet ownership and the sanctity of domestic animals. Many pet owners find it difficult to reconcile the idea of their pets being used in this manner, regardless of the zoo's assurances of ethical practices. The discussion prompts broader questions about how we value different animal lives and the intersection of pet ownership and wildlife conservation. 'She Wasn't Supposed to Exist': U.S. Scientists Finally Confirm Spotted Supermom After 40 Years of Denial and Cultural Cover-Up Implications for Zoos Worldwide The Danish zoo's initiative may set a precedent or at least ignite discussions among zoos globally about how they procure food for their predators. The decision to accept unwanted pets as food sources could influence policies and practices in other institutions seeking to enhance animal welfare by mimicking natural diets. Moreover, this practice could lead to a re-evaluation of how zoos engage with the public in terms of conservation and education. By involving communities in the feeding process, zoos might foster a greater understanding of wildlife ecology. However, they must tread carefully to maintain public trust and ensure ethical standards are upheld. As zoos strive to balance animal welfare, ethical considerations, and public perception, the Danish zoo's practice invites us to ponder: Are we ready to redefine the roles of domestic animals in wildlife conservation, and what ethical boundaries should guide these decisions? This article is based on verified sources and supported by editorial technologies. Did you like it? 4.5/5 (28)
Euronews
3 days ago
- Euronews
Experimental pill helped with weight loss in Eli Lilly trial
An experimental once-daily pill to treat obesity can help people lose a significant amount of weight, according to new data from drugmaker Eli Lilly. The medicine, called orforglipron, belongs to a class of blockbuster weight loss drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists, which work by mimicking a hormone that makes people feel full for longer. Most GLP-1 drugs – like Ozempic, Wegovy, and Mounjaro – must be injected, so pharmaceutical companies have been racing to find alternatives. Lilly's pill may be the first to get there. The company plans to ask regulators to approve orforglipron by the end of the year, and said it is ready to begin rolling out the medicine globally. If it's approved, the pill could offer 'a convenient alternative to injectable treatments,' Kenneth Custer, executive vice president and president of Lilly Cardiometabolic Health, said in a statement. The clinical trial included more than 3,100 adults who were overweight or obese and had a weight-related health problem other than patients with diabetes. After 72 weeks, the participants taking 36mg of orforglipron per day lost an average of 12.4 kilograms, or 12.4 per cent of their body weight. Notably, that is not as much as people on other anti-obesity medicines. In one study, for example, people taking Novo Nordisk's Wegovy lost 13.2 per cent of their weight and those on Lilly's Zepbound lost 20.2 per cent over 72 weeks. But the ability to take orforglipron as a daily pill rather than an injectable jab may drive up demand. In the study, other cardiovascular risk factors also improved for patients, including their cholesterol, triglycerides, and blood pressure. Orforglipron's side effects were mostly gastrointestinal, for example, constipation, diarrhoea, and vomiting, similar to other weight loss drugs. Simon Cork, a senior lecturer in physiology at Anglia Ruskin University in the United Kingdom, said the findings are a 'positive step forward in the development of these class of drugs'. Eli Lilly reported the data in a news release, and it has not yet been published in a peer-reviewed journal. The company said it will release more details next month at the European Association for the Study of Diabetes (EASD). "Obesity is one of the most pressing global health challenges of our time, driving global chronic disease burden and impacting more than one billion people worldwide," Custer said.
